Nanobiotix (NBTX) Competitors $4.07 +0.29 (+7.68%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NBTX vs. AUTL, ERAS, CGEM, CRGX, AVXL, TRDA, ABUS, CRMD, TECX, and EXAIShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Autolus Therapeutics (AUTL), Erasca (ERAS), Cullinan Therapeutics (CGEM), CARGO Therapeutics (CRGX), Anavex Life Sciences (AVXL), Entrada Therapeutics (TRDA), Arbutus Biopharma (ABUS), CorMedix (CRMD), Tectonic Therapeutic (TECX), and Exscientia (EXAI). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Autolus Therapeutics Erasca Cullinan Therapeutics CARGO Therapeutics Anavex Life Sciences Entrada Therapeutics Arbutus Biopharma CorMedix Tectonic Therapeutic Exscientia Nanobiotix (NASDAQ:NBTX) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability. Do insiders and institutionals believe in NBTX or AUTL? 38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is NBTX or AUTL more profitable? Nanobiotix's return on equity of 0.00% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A Autolus Therapeutics N/A -63.65%-36.54% Which has better valuation & earnings, NBTX or AUTL? Nanobiotix has higher revenue and earnings than Autolus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix$39.18M4.89-$42.97MN/AN/AAutolus Therapeutics$1.70M449.22-$208.38M-$1.21-2.37 Does the media refer more to NBTX or AUTL? In the previous week, Autolus Therapeutics had 18 more articles in the media than Nanobiotix. MarketBeat recorded 20 mentions for Autolus Therapeutics and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 1.16 beat Autolus Therapeutics' score of 0.24 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer NBTX or AUTL? Nanobiotix currently has a consensus target price of $11.50, indicating a potential upside of 182.66%. Autolus Therapeutics has a consensus target price of $10.15, indicating a potential upside of 253.66%. Given Autolus Therapeutics' higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor NBTX or AUTL? Autolus Therapeutics received 214 more outperform votes than Nanobiotix when rated by MarketBeat users. Likewise, 67.77% of users gave Autolus Therapeutics an outperform vote while only 64.71% of users gave Nanobiotix an outperform vote. CompanyUnderperformOutperformNanobiotixOutperform Votes1164.71% Underperform Votes635.29% Autolus TherapeuticsOutperform Votes22567.77% Underperform Votes10732.23% Which has more risk & volatility, NBTX or AUTL? Nanobiotix has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. SummaryAutolus Therapeutics beats Nanobiotix on 9 of the 14 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$191.75M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E RatioN/A4.8587.8613.46Price / Sales4.89374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book-101.7110.216.946.30Net Income-$42.97M$153.61M$119.12M$225.93M7 Day Performance0.46%-2.00%-1.84%-1.32%1 Month Performance-15.42%-7.47%-3.65%0.60%1 Year Performance-32.19%31.80%31.64%26.23% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix2.3432 of 5 stars$4.07+7.7%$11.50+182.7%-33.5%$191.75M$39.18M0.00100Positive NewsAUTLAutolus Therapeutics3.4682 of 5 stars$2.87+2.5%$10.15+253.7%-36.5%$763.68M$1.70M0.00330Analyst UpgradeERASErasca2.8027 of 5 stars$2.64-5.4%$6.08+130.4%+17.3%$746.41MN/A0.00126Analyst ForecastAnalyst RevisionCGEMCullinan Therapeutics1.8429 of 5 stars$12.58-4.0%$31.67+151.7%+43.6%$732.53M$18.94M0.0030Analyst RevisionCRGXCARGO Therapeutics1.677 of 5 stars$15.82-1.8%$30.33+91.7%+8.0%$728.20MN/A-3.71116AVXLAnavex Life Sciences3.7059 of 5 stars$8.57+1.1%$40.00+366.7%+21.1%$726.74MN/A0.0040Upcoming EarningsTRDAEntrada Therapeutics1.9803 of 5 stars$17.93+0.9%$24.00+33.9%+9.9%$670.94M$129.01M11.28110ABUSArbutus Biopharma2.7999 of 5 stars$3.44-1.4%$5.50+59.9%+87.0%$651.85M$18.14M-8.0073Analyst ForecastCRMDCorMedix2.6748 of 5 stars$10.74-3.0%$15.20+41.5%+184.1%$651.70M$60,000.00-13.2630Insider TradeTECXTectonic Therapeutic3.5107 of 5 stars$43.00-2.3%$72.25+68.0%N/A$634.25MN/A0.00120Analyst ForecastGap UpEXAIExscientia2.2551 of 5 stars$4.84flat$7.00+44.6%N/A$632.93M$25.60M0.00280News Coverage Related Companies and Tools Related Companies Autolus Therapeutics Competitors Erasca Competitors Cullinan Therapeutics Competitors CARGO Therapeutics Competitors Anavex Life Sciences Competitors Entrada Therapeutics Competitors Arbutus Biopharma Competitors CorMedix Competitors Tectonic Therapeutic Competitors Exscientia Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NBTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
